Immune and Histopathological Biomarkers for Prognosis and Neoadjuvant Immunotherapy Response in Intrahepatic Cholangiocarcinoma
Rattachement africain : sg, cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: The tumor microenvironment (TME) plays a critical role in determining the clinical outcomes in patients with intrahepatic cholangiocarcinoma (iCCA). This study investigates the prognostic significance of CD8+ T cells and regulatory T cells (Tregs) in tumor-infiltrating lymphocytes (TILs) and their relationship to histopathological features. Methods: Immunofluorescence analysis was conducted on a cohort of 34 resected iCCA cases to assess CD8+ T cell and Treg densities. Statistical correlations with survival and immune and histopathological features were examined. Validation was performed on an independent cohort of 95 iCCA pre-neoadjuvant therapy (NAT) biopsy specimens to assess the prognostic power of the immune and histopathological features to survival and NAT response. Results: In the cohort of resected iCCA cases, immunofluorescence revealed that increased CD8+ T-cell infiltration is associated with improved survival (p = 0.018), underscoring their role in anti-tumor immunity. Conversely, higher density of Tregs is linked to poorer survival (p = 0.038), suggesting its tumor-promoting, immunosuppressive effects. Intriguingly, CD8+ T cells and Tregs are associated with distinct histopathological features, with CD8+ T cells correlating with dense tumor-infiltrating lymphocytes (TILs, Pearson’s R = 0.498; p = 0.004) and Tregs being more prevalent in regions of tumor budding (TB, Pearson’s R = 0.382; p = 0.029). These observations were validated in an independent pre-NAT cohort (n = 95), whereby higher TIL density, particularly increased CD8+ T cells and reduced Treg, and lower TB predict favorable response to NAT, as shown by improved overall and disease-free survival. Conclusion: These findings provide critical insights for stratifying patients and highlight the potential for optimizing immune-targeted therapies in patients with iCCA.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Immune and Histopathological Biomarkers for Prognosis and Neoadjuvant Immunotherapy Response in Intrahepatic Cholangiocarcinoma
- Date Crossref
- 18/07/2025
- Éditeur
- S. Karger AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
SingHealth Duke-NUS Academic Medical Centre pays non établi dans la noticeÉtablissement de santé
-
Duke-NUS Medical School pays non établi dans la noticeUniversité ou école supérieure
-
KK Women's and Children's Hospital pays non établi dans la noticeÉtablissement de santé
-
Fudan University Department of Liver Surgery and Transplantation pays non établi dans la noticeUniversité ou école supérieure
-
Zhongshan Hospital pays non établi dans la noticeÉtablissement de santé
-
Sun Yat-sen University pays non établi dans la noticeUniversité ou école supérieure
-
Singapore General Hospital Department of Anatomical Pathology pays non établi dans la noticeÉtablissement de santé
-
Translational Immunology Institute (TII) pays non établi dans la noticeStructure de recherche
-
Department of Pathology and Laboratory Medicine pays non établi dans la noticeStructure de recherche
SingHealth Duke-NUS Academic Medical Centre, Duke-NUS Medical School et KK Women's and Children's Hospital, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.